The Evolving Treatment Landscape for High-Risk MDS

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: December 16, 2016
Expiration Date: December 16, 2017

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Risk-stratification of patients with myelodysplastic syndromes (MDS) is essential to appropriate treatment selection and optimization of patient outcomes. In this activity, Dr. Bart Scott will provide an overview of risk assessment tools to prognosticate patients and outline associated treatment options based on patient-specific factors. In addition, Dr. Scott will summarize new therapeutic options being investigated for the treatment of patients with high-risk MDS.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in myelodysplastic syndromes.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify patients with high-risk myelodysplastic syndromes (MDS) through appropriate risk assessment and prognostication tools
  • Outline treatment strategies for high-risk MDS based on patient factors such as age, frailty, and cytogenetic abnormalities
  • Recognize novel therapies and drug combinations under investigation for the treatment of patients with high-risk MDS


The Evolving Treatment Landscape for High-Risk MDS – Bart Scott, MD

Instructions for Participation and Credit

This activity is eligible for credit through December 16, 2017. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Bart Scott, MD
Associate Professor
University of Washington Medical Center
Associate Member
Fred Hutchinson Cancer Research Center
Seattle, Washington

Dr. Bart Scott received his medical degree from the University of South Alabama in Mobile, Alabama. He is currently an associate professor at the University of Washington Medical Center and an associate member of the Fred Hutchinson Cancer Research Center in Seattle. In addition, Dr. Scott is an attending physician at the University of Washington Medical Center and the Seattle Cancer Care Alliance where he is also Director of Hematology and Hematologic Malignancies.

Dr. Scott is a diplomate of the American Board of Internal Medicine (ABIM) and ABIM board certified in in medical oncology. He holds professional memberships in the American Society of Hematology, American Society of Clinical Oncology, American Association for Cancer Research, American Society for Blood and Marrow Transplantation, and the Southwest Oncology Group, among others. He is a journal reviewer for Blood, Biology of Blood and Marrow Transplantation, New England Journal of Medicine, Leukemia, Haematologica, and the British Journal of Haematology. Dr. Scott has authored numerous manuscripts, book chapters, and abstracts on myelodysplastic syndrome and myeloproliferative disorders; he believes patient education is key so that the patient can guide the physician to meet his or her needs.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-16-131-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the login/registration on the home page of this site.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Bart Scott has received honoraria related to formal advisory activities from Agios, speakers’ bureau activities from Alexion, Celgene Corporation, and Incyte Corporation, as well as consultant fees from Alexion and Celgene. He has received grant support related to research activities from Celgene and Novartis AG.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Physician Payments, Sunshine Act

MediCom Worldwide, Inc. complies with the Physician Payments Sunshine Act as part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfer of value provided to any covered recipient under the ACA.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.

©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.